0 XP   0   0   0

BAL PHARMA LTD.
Buy, Hold or Sell?

Should you buy, hold or sell BAL PHARMA LTD.?

I guess you are interested in BAL PHARMA LTD.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse BAL PHARMA LTD.

Let's start. I'm going to help you getting a better view of BAL PHARMA LTD.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is BAL PHARMA LTD. even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how BAL PHARMA LTD. is doing in the market. If the company is worth buying. The latest step is to find out how other investors value BAL PHARMA LTD.. The closing price on 2023-01-25 was INR86.60 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
BAL PHARMA LTD. Daily Candlestick Chart
BAL PHARMA LTD. Daily Candlestick Chart
Summary









1. Valuation of BAL PHARMA LTD.




Current price per share

INR86.60

2. Growth of BAL PHARMA LTD.




Is BAL PHARMA LTD. growing?

Current yearPrevious yearGrowGrow %
How rich?$7.1m$6.5m$632k8.8%

How much money is BAL PHARMA LTD. making?

Current yearPrevious yearGrowGrow %
Making money$690.2k$583.3k$106.8k15.5%
Net Profit Margin2.0%1.9%--

How much money comes from the company's main activities?

3. Financial Health of BAL PHARMA LTD.




Comparing to competitors in the industry




  Industry Rankings ()  



Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

1.1. Profitability of BAL PHARMA LTD..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit BAL PHARMA LTD. earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare BAL PHARMA LTD. to the  industry mean.
  • A Net Profit Margin of 2.0% means that ₹0.02 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BAL PHARMA LTD.:

  • The MRQ is 2.0%. The company is making a profit. +1
  • The TTM is 2.0%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ2.0%TTM2.0%0.0%
TTM2.0%YOY1.9%+0.1%
TTM2.0%5Y-0.4%+2.4%
5Y-0.4%10Y-0.4%0.0%
1.1.2. Return on Assets

Shows how efficient BAL PHARMA LTD. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare BAL PHARMA LTD. to the  industry mean.
  • 2.2% Return on Assets means that BAL PHARMA LTD. generated ₹0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BAL PHARMA LTD.:

  • The MRQ is 2.2%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.2%TTM2.2%0.0%
TTM2.2%YOY2.0%+0.2%
TTM2.2%5Y0.1%+2.0%
5Y0.1%10Y0.1%0.0%
1.1.3. Return on Equity

Shows how efficient BAL PHARMA LTD. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare BAL PHARMA LTD. to the  industry mean.
  • 9.6% Return on Equity means BAL PHARMA LTD. generated ₹0.10 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BAL PHARMA LTD.:

  • The MRQ is 9.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 9.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ9.6%TTM9.6%0.0%
TTM9.6%YOY8.9%+0.7%
TTM9.6%5Y0.2%+9.4%
5Y0.2%10Y0.2%0.0%

1.2. Operating Efficiency of BAL PHARMA LTD..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient BAL PHARMA LTD. is operating .

  • Measures how much profit BAL PHARMA LTD. makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare BAL PHARMA LTD. to the  industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BAL PHARMA LTD.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y0.8%-0.8%
5Y0.8%10Y0.8%0.0%
1.2.2. Operating Ratio

Measures how efficient BAL PHARMA LTD. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 1.55 means that the operating costs are ₹1.55 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of BAL PHARMA LTD.:

  • The MRQ is 1.551. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.551. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.551TTM1.5510.000
TTM1.551YOY1.535+0.016
TTM1.5515Y1.521+0.030
5Y1.52110Y1.5210.000

1.3. Liquidity of BAL PHARMA LTD..

1.3. Liquidity
1.3.1. Current Ratio

Measures if BAL PHARMA LTD. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 1.11 means the company has ₹1.11 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of BAL PHARMA LTD.:

  • The MRQ is 1.114. The company is just able to pay all its short-term debts.
  • The TTM is 1.114. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.114TTM1.1140.000
TTM1.114YOY1.076+0.038
TTM1.1145Y1.081+0.034
5Y1.08110Y1.0810.000
1.3.2. Quick Ratio

Measures if BAL PHARMA LTD. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare BAL PHARMA LTD. to the  industry mean.
  • A Quick Ratio of 0.48 means the company can pay off ₹0.48 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BAL PHARMA LTD.:

  • The MRQ is 0.485. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.485. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.485TTM0.4850.000
TTM0.485YOY0.460+0.025
TTM0.4855Y0.439+0.045
5Y0.43910Y0.4390.000

1.4. Solvency of BAL PHARMA LTD..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of BAL PHARMA LTD. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare BAL PHARMA LTD. to industry mean.
  • A Debt to Asset Ratio of 0.78 means that BAL PHARMA LTD. assets are financed with 77.5% credit (debt) and the remaining percentage (100% - 77.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BAL PHARMA LTD.:

  • The MRQ is 0.775. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.775. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.775TTM0.7750.000
TTM0.775YOY0.778-0.002
TTM0.7755Y0.783-0.008
5Y0.78310Y0.7830.000
1.4.2. Debt to Equity Ratio

Measures if BAL PHARMA LTD. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare BAL PHARMA LTD. to the  industry mean.
  • A Debt to Equity ratio of 344.6% means that company has ₹3.45 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BAL PHARMA LTD.:

  • The MRQ is 3.446. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.446. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ3.446TTM3.4460.000
TTM3.446YOY3.485-0.039
TTM3.4465Y3.408+0.039
5Y3.40810Y3.4080.000

2. Market Valuation of BAL PHARMA LTD.

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings BAL PHARMA LTD. generates.

  • Above 15 is considered overpriced but always compare BAL PHARMA LTD. to the  industry mean.
  • A PE ratio of 29.93 means the investor is paying ₹29.93 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BAL PHARMA LTD.:

  • The EOD is 24.032. Very good. +2
  • The MRQ is 29.929. Very good. +2
  • The TTM is 29.929. Very good. +2
Trends
Current periodCompared to+/- 
EOD24.032MRQ29.929-5.897
MRQ29.929TTM29.9290.000
TTM29.929YOY16.801+13.128
TTM29.9295Y17.333+12.596
5Y17.33310Y17.3330.000
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of BAL PHARMA LTD..

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of BAL PHARMA LTD.:

  • The MRQ is 26.571. Seems overpriced? -1
  • The TTM is 26.571. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ26.571TTM26.5710.000
TTM26.571YOY7.086+19.485
TTM26.5715Y11.609+14.962
5Y11.60910Y11.6090.000

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of BAL PHARMA LTD. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 2.87 means the investor is paying ₹2.87 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of BAL PHARMA LTD.:

  • The EOD is 2.306. Good. +1
  • The MRQ is 2.871. Good. +1
  • The TTM is 2.871. Good. +1
Trends
Current periodCompared to+/- 
EOD2.306MRQ2.871-0.566
MRQ2.871TTM2.8710.000
TTM2.871YOY1.493+1.378
TTM2.8715Y1.760+1.111
5Y1.76010Y1.7600.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of BAL PHARMA LTD. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.5701.5700%4.002-61%9.390-83%9.390-83%
Book Value Growth--1.0961.0960%1.177-7%1.009+9%1.009+9%
Book Value Per Share--37.56237.5620%35.992+4%37.009+1%37.009+1%
Book Value Per Share Growth--1.0441.0440%1.125-7%0.974+7%0.974+7%
Current Ratio--1.1141.1140%1.076+4%1.081+3%1.081+3%
Debt To Asset Ratio--0.7750.7750%0.7780%0.783-1%0.783-1%
Debt To Equity Ratio--3.4463.4460%3.485-1%3.408+1%3.408+1%
Dividend Per Share--0.9520.9520%-+100%0.748+27%0.748+27%
Eps--3.6033.6030%3.199+13%0.214+1587%0.214+1587%
Eps Growth--1.1261.1260%2.371-52%0.091+1143%0.091+1143%
Free Cash Flow Per Share--12.35512.3550%12.3910%9.221+34%9.221+34%
Free Cash Flow Per Share Growth--0.9970.9970%0.974+2%8.511-88%8.511-88%
Free Cash Flow To Equity Per Share--12.35512.3550%12.3910%5.700+117%5.700+117%
Free Cash Flow To Equity Per Share Growth--0.9970.9970%11.074-91%3.906-74%3.906-74%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin--0.0200.0200%0.019+5%-0.004+120%-0.004+120%
Operating Margin----0%-0%0.008-100%0.008-100%
Operating Ratio--1.5511.5510%1.535+1%1.521+2%1.521+2%
Pb Ratio2.306-25%2.8712.8710%1.493+92%1.760+63%1.760+63%
Pe Ratio24.032-25%29.92929.9290%16.801+78%17.333+73%17.333+73%
Peg Ratio--26.57126.5710%7.086+275%11.609+129%11.609+129%
Price Per Share86.600-25%107.850107.8500%53.750+101%66.163+63%66.163+63%
Price To Total Gains Ratio34.346-25%42.77442.7740%13.431+218%13.600+215%13.600+215%
Profit Growth--1.1831.1830%2.388-50%0.115+926%0.115+926%
Quick Ratio--0.4850.4850%0.460+5%0.439+10%0.439+10%
Return On Assets--0.0220.0220%0.020+9%0.001+1800%0.001+1800%
Return On Equity--0.0960.0960%0.089+8%0.002+4682%0.002+4682%
Revenue Growth--1.1221.1220%1.464-23%1.116+1%1.116+1%
Total Gains Per Share--2.5212.5210%4.002-37%10.138-75%10.138-75%
Total Gains Per Share Growth--0.6300.6300%2.421-74%0.944-33%0.944-33%
Usd Book Value--7194565.2007194565.2000%6562492.800+10%6685200.675+8%6685200.675+8%
Usd Book Value Change Per Share--0.0190.0190%0.049-61%0.116-83%0.116-83%
Usd Book Value Per Share--0.4620.4620%0.443+4%0.455+1%0.455+1%
Usd Dividend Per Share--0.0120.0120%-+100%0.009+27%0.009+27%
Usd Eps--0.0440.0440%0.039+13%0.003+1587%0.003+1587%
Usd Free Cash Flow--2366409.3002366409.3000%2259239.400+5%1685355.225+40%1685355.225+40%
Usd Free Cash Flow Per Share--0.1520.1520%0.1520%0.113+34%0.113+34%
Usd Free Cash Flow To Equity Per Share--0.1520.1520%0.1520%0.070+117%0.070+117%
Usd Price Per Share1.065-25%1.3271.3270%0.661+101%0.814+63%0.814+63%
Usd Profit--690214.500690214.5000%583315.200+18%59150.700+1067%59150.700+1067%
Usd Revenue--34589383.50034589383.5000%30815017.800+12%28531322.925+21%28531322.925+21%
Usd Total Gains Per Share--0.0310.0310%0.049-37%0.125-75%0.125-75%
 EOD+3 -2MRQTTM+0 -0YOY+20 -205Y+27 -1410Y+27 -14

3.2. Fundamental Score

Let's check the fundamental score of BAL PHARMA LTD. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1524.032
Price to Book Ratio (EOD)Between0-12.306
Net Profit Margin (MRQ)Greater than00.020
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.485
Current Ratio (MRQ)Greater than11.114
Debt to Asset Ratio (MRQ)Less than10.775
Debt to Equity Ratio (MRQ)Less than13.446
Return on Equity (MRQ)Greater than0.150.096
Return on Assets (MRQ)Greater than0.050.022
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of BAL PHARMA LTD. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose86.350
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets2,605,327
Total Liabilities2,020,403
Total Stockholder Equity586,268
 As reported
Total Liabilities 2,020,403
Total Stockholder Equity+ 586,268
Total Assets = 2,605,327

Assets

Total Assets2,605,327
Total Current Assets1,845,706
Long-term Assets1,845,706
Total Current Assets
Cash And Cash Equivalents 11,128
Short-term Investments 49,717
Net Receivables 753,123
Inventory 743,956
Other Current Assets 4,429
Total Current Assets  (as reported)1,845,706
Total Current Assets  (calculated)1,562,353
+/- 283,353
Long-term Assets
Goodwill 38,286
Intangible Assets 83,016
Long-term Assets  (as reported)759,623
Long-term Assets  (calculated)121,302
+/- 638,321

Liabilities & Shareholders' Equity

Total Current Liabilities1,656,448
Long-term Liabilities363,955
Total Stockholder Equity586,268
Total Current Liabilities
Short Long Term Debt 766,263
Accounts payable 655,639
Other Current Liabilities 34,889
Total Current Liabilities  (as reported)1,656,448
Total Current Liabilities  (calculated)1,456,791
+/- 199,657
Long-term Liabilities
Long term Debt 270,134
Capital Lease Obligations Min Short Term Debt30,156
Long-term Liabilities Other -3
Long-term Liabilities  (as reported)363,955
Long-term Liabilities  (calculated)300,287
+/- 63,668
Total Stockholder Equity
Retained Earnings 135,813
Total Stockholder Equity (as reported)586,268
Total Stockholder Equity (calculated)135,813
+/- 450,455
Other
Capital Stock148,224
Common Stock Shares Outstanding 15,572
Net Debt 1,025,269
Net Invested Capital 1,622,665
Net Working Capital 189,258



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
> Total Assets 
0
0
2,613,083
2,383,871
2,400,804
2,605,327
2,605,3272,400,8042,383,8712,613,08300
   > Total Current Assets 
1,645,502
1,847,698
1,830,453
1,611,553
1,641,473
1,845,706
1,845,7061,641,4731,611,5531,830,4531,847,6981,645,502
       Cash And Cash Equivalents 
0
0
24,361
8,587
10,234
11,128
11,12810,2348,58724,36100
       Short-term Investments 
0
0
17,097
26,479
29,475
49,717
49,71729,47526,47917,09700
       Net Receivables 
663,619
701,404
711,011
558,592
671,970
753,123
753,123671,970558,592711,011701,404663,619
       Inventory 
547,308
664,933
697,511
677,113
603,853
743,956
743,956603,853677,113697,511664,933547,308
       Other Current Assets 
380,257
438,993
373,513
337,493
3,136
4,429
4,4293,136337,493373,513438,993380,257
   > Long-term Assets 
0
0
794,017
772,575
759,331
759,623
759,623759,331772,575794,01700
       Property Plant Equipment 
570,165
633,740
644,778
637,695
0
0
00637,695644,778633,740570,165
       Goodwill 
0
0
38,286
38,286
38,286
38,286
38,28638,28638,28638,28600
       Intangible Assets 
0
0
57,119
64,282
72,482
83,016
83,01672,48264,28257,11900
       Long-term Assets Other 
0
0
0
1
43,278
-4,004
-4,00443,2781000
> Total Liabilities 
0
0
2,010,871
1,930,494
1,867,268
2,020,403
2,020,4031,867,2681,930,4942,010,87100
   > Total Current Liabilities 
1,432,400
1,544,051
1,632,478
1,594,915
1,525,329
1,656,448
1,656,4481,525,3291,594,9151,632,4781,544,0511,432,400
       Short Long Term Debt 
0
0
947,452
953,089
860,908
766,263
766,263860,908953,089947,45200
       Accounts payable 
544,253
499,577
473,379
386,740
471,665
655,639
655,639471,665386,740473,379499,577544,253
       Other Current Liabilities 
101,061
176,446
129,954
168,208
77,356
34,889
34,88977,356168,208129,954176,446101,061
   > Long-term Liabilities 
0
0
378,494
335,579
341,939
363,955
363,955341,939335,579378,49400
       Capital Lease Obligations Min Short Term Debt
0
0
0
19,636
19,232
30,156
30,15619,23219,636000
       Long-term Liabilities Other 
0
0
0
-67
1
-3
-31-67000
       Deferred Long Term Liability 
45,921
43,900
56,145
63,632
0
0
0063,63256,14543,90045,921
> Total Stockholder Equity
0
0
666,430
524,261
535,814
586,268
586,268535,814524,261666,43000
   Common Stock
141,724
141,724
141,724
141,724
0
0
00141,724141,724141,724141,724
   Retained Earnings Total Equity000000
   Accumulated Other Comprehensive Income 000000
   Capital Surplus 000000
   Treasury Stock000000
   Other Stockholders Equity 
942
-1,459
-5,704
-8,606
0
0
00-8,606-5,704-1,459942



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue2,812,145
Cost of Revenue-1,697,335
Gross Profit1,114,8101,114,810
 
Operating Income (+$)
Gross Profit1,114,810
Operating Expense-2,665,219
Operating Income146,926-1,550,409
 
Operating Expense (+$)
Research Development0
Selling General Administrative175,223
Selling And Marketing Expenses-
Operating Expense2,665,219175,223
 
Net Interest Income (+$)
Interest Income3,701
Interest Expense-85,081
Net Interest Income-101,716-81,380
 
Pretax Income (+$)
Operating Income146,926
Net Interest Income-101,716
Other Non-Operating Income Expenses-
Income Before Tax (EBT)91,825146,926
EBIT - interestExpense = -85,081
56,115
141,196
Interest Expense85,081
Earnings Before Interest and Taxes (ebit)-176,906
Earnings Before Interest and Taxes (ebitda)267,307
 
After tax Income (+$)
Income Before Tax91,825
Tax Provision-34,775
Net Income From Continuing Ops57,04957,050
Net Income56,115
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-101,716
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
IPAXU.NASDAQ
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of IPAXU.NASDAQ.

IPAXU.NASDAQ Daily Candlestick Chart
CLT.CC
1 hour ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of CLT.CC.

CLT.CC Daily Candlestick Chart
CLB.CC
1 hour ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of CLB.CC.

CLB.CC Daily Candlestick Chart
CKB.CC
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CKB.CC.

CKB.CC Daily Candlestick Chart
TR.V
1 hour ago

I found you a MACD Bullish Hidden Divergence on the daily chart of TR.V.

TR.V Daily Candlestick Chart
NIFLN0000.CM
1 hour ago

I found you a RSI Bullish Reversal Divergence on the daily chart of NIFLN0000.CM.

NIFLN0000.CM Daily Candlestick Chart
AUTON0000.CM
1 hour ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of AUTON0000.CM.

AUTON0000.CM Daily Candlestick Chart
VONEN0000.CM
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VONEN0000.CM.

VONEN0000.CM Daily Candlestick Chart
MELE.BR
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MELE.BR.

MELE.BR Daily Candlestick Chart
REN.JSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of REN.JSE.

REN.JSE Daily Candlestick Chart
CEU.PSE
2 hours ago

I found you a Golden Cross on the daily chart of CEU.PSE.

CEU.PSE Daily Candlestick Chart
HKY.OL
2 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of HKY.OL.

HKY.OL Daily Candlestick Chart
SLF-PK.TO
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SLF-PK.TO.

SLF-PK.TO Daily Candlestick Chart
DECCANCE.NSE
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of DECCANCE.NSE.

DECCANCE.NSE Daily Candlestick Chart
DECIPHER.BSE
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of DECIPHER.BSE.

DECIPHER.BSE Daily Candlestick Chart
DECCANCE.BSE
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of DECCANCE.BSE.

DECCANCE.BSE Daily Candlestick Chart
CTE.NSE
2 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of CTE.NSE.

CTE.NSE Daily Candlestick Chart
CRANEX.BSE
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CRANEX.BSE.

CRANEX.BSE Daily Candlestick Chart
CPL.BSE
2 hours ago

I found you a Golden Cross on the daily chart of CPL.BSE.

CPL.BSE Daily Candlestick Chart
CONCOR.NSE
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of CONCOR.NSE.

CONCOR.NSE Daily Candlestick Chart
COMSYN.BSE
2 hours ago

I found you a Death Cross on the daily chart of COMSYN.BSE.

COMSYN.BSE Daily Candlestick Chart
COMFINTE.BSE
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of COMFINTE.BSE.

COMFINTE.BSE Daily Candlestick Chart
COFFEEDAY.NSE
2 hours ago

I found you a Death Cross on the daily chart of COFFEEDAY.NSE.

COFFEEDAY.NSE Daily Candlestick Chart